About CDK4/6 inhibitors: advances in breast cancer management
Join Dr Nadia Harbeck and Professor Alessandra Gennari in this podcast series on risk assessment and CDK4/6 inhibitors for the treatment of early breast cancer.
This podcast is intended for registered Healthcare Professionals only.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Episode 6: The rapidly evolving treatment landscape for high-risk early breast cancer: Choosing the optimal treatment option
How might the early breast cancer treatment landscape change over the next 2 years? Dr Nadia Harbeck and Professor Michael Gnant review findings presented at ESMO 2023 and discuss approaches to optimal treatment selection in a rapidly evolving treatment landscape.
15 Nov 2023
Episode 5: The many definitions for ‘high risk of recurrence’ in early breast cancer: What should inform clinical practice?
Recurrence risk is an important factor that must be considered in the treatment of early breast cancer. Dr Nadia Harbeck and Professor Michael Gnant discuss how recurrence risk and other factors can inform treatment selection.
15 Nov 2023
Episode 4: CDK4/6 inhibitors in the early breast cancer setting: Is the evidence clear?
Dr Nadia Harbeck and Professor Michael Gnant review the latest clinical trial evidence for CDK4/6 inhibitors in the early breast cancer setting and discuss what the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval of abemaciclib means for clinicians and people with early breast cancer.
22 Sept 2022
Episode 3: Explanations for the divergent results of PALLAS/PENELOPE-B and monarchE trials
Dr Nadia Harbeck and Professor Alessandra Gennari review the completed clinical trials for CDK4/6 inhibitors in early breast cancer, namely PALLAS and PENELOPE-B for palbociclib and monarchE for abemaciclib. The divergent results for palbociclib and abemaciclib were unexpected, particularly as both proved effective in the metastatic setting and are now standard therapy for this indication. Dr Harbeck and Professor Gennari share their views on the possible reasons for the different outcomes with palbociclib and abemaciclib in early breast cancer.
22 Sept 2022
Episode 2: The RxPonder trial – identifying patients most likely to benefit from adjuvant therapy
Dr Nadia Harbeck and Professor Alessandra Gennari delve deeper into the RxPonder trial to explore the design and primary outcomes of the trial. Dr Harbeck and Professor Gennari discuss how RxPonder validated the use of the 21-gene expression assay as a tool to identify patients who could be spared chemotherapy.
22 Sept 2022
Episode 1: The use of biomarkers to inform and individualise treatment decisions for patients with early breast cancer
Dr Nadia Harbeck and Professor Alessandra Gennari discuss ground-breaking trials, including the TailorX and RxPonder trials, that validated the use of gene expression assays to inform therapy decisions for patients with early breast cancer. Dr Harbeck also describes the ADAPT series, which combines gene expression assays with endocrine response to individualise therapy.
Contact CDK4/6 inhibitors: advances in breast cancer management
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of CDK4/6 inhibitors: advances in breast cancer management?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
